Rhythm Biosciences Share Price and Company Fundamentals
Last traded: Today at 5:17 AM
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Key Metrics
PE ratio
-
PB ratio
87.50
Dividend yield
-
Beta
0.31
Market cap
$57.24M
Enterprise value
$53.60M
Company profile
| Industry / Sector | Diagnostics & Research / Healthcare |
|---|---|
| Website | https://rhythmbio.com |
| Mailing address | Bio21 Institute 30 Flemington Road Parkville VIC 3010 Australia |
| Phone / Fax | 61 3 8256 2880 / 61 3 9614 0550 |
Dividends
More: Rhythm Biosciences Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Rhythm Biosciences paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.RHY dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Rhythm Biosciences.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. David Atkins M.B.A., Ph.D. | CEO & Director | 60 |
Profitability and management effectiveness
Profit margin
-119.97%
Operating margin
-17113.08%
Return on assets
-107.16%
Return on equity
-501.54%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Rhythm Biosciences is 57.24M and its enterprise value is 53.60M. The enterprise value to revenue ratio of RHY is 16.79. The enterprise value to EBITDA ratio of RHY is -15.17.
The RHY's stocks Beta value is 0.31 making it 69% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Rhythm Biosciences (RHY)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Polynovo (PNV)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Rhythm Biosciences (ASX:RHY) Frequently Asked Questions
1. What is Rhythm Biosciences's Stock Symbol?
Rhythm Biosciences trades on ASX under the ticker symbol "RHY".
2. What is Rhythm Biosciences's stock price today?
One share of RHY stock can currently be purchased for approximately $0.175.
3. How can I contact Rhythm Biosciences?
Rhythm Biosciences's mailing address is Bio21 Institute 30 Flemington Road Parkville VIC 3010 Australia. The company can be reached via phone at 61 3 8256 2880.
4. What is Rhythm Biosciences's official website?
The official website of Rhythm Biosciences is https://rhythmbio.com.